Bradley Garman, University of Pennsylvania
Ioannis N. Anastopoulos, University of PennsylvaniaFollow
Clemens Krepler, The Wistar InstituteFollow
Patricia Brafford, The Wistar InstituteFollow
Katrin Sproesser, The Wistar InstituteFollow
Yuchao Jiang, University of Pennsylvania
Bradley Wubbenhorst, University of PennsylvaniaFollow
Ravi Amaravadi, University of Pennsylvania
Joseph Bennett, Christiana Care Health SystemFollow
Marilda Beqiri, The Wistar InstituteFollow
David Elder, University of Pennsylvania
Keith T. Flaherty, Massachusetts General HospitalFollow
Dennie T. Frederick, Massachusetts General HospitalFollow
Tara C. Gangadhar, University of Pennsylvania
Michael Guarino, Christiana Care Health SystemFollow
David Hoon, Providence Saint John's Health CenterFollow
Giorgos Karakousis, University of PennsylvaniaFollow
Qin Liu, The Wistar InstituteFollow
Nandita Mitra, University of Pennsylvania
Nicholas J. Petrelli, Christiana Care Health SystemFollow
Lynn Schuchter, University of Pennsylvania,Follow
Batool Shannan, The Wistar InstituteFollow
Carol L. Shields, Thomas Jefferson UniversityFollow
Jennifer Wargo, University of Texas MD Anderson Cancer CenterFollow
Brandon Wenz, University of Pennsylvania,
Melissa A. Wilson, NYU School of Medicine, NYU Langone Medical CenterFollow
Min Xiao, The Wistar InstituteFollow
Wei Xu, University of PennsylvaniaFollow
Xaiowei Xu, University of Pennsylvania
Xiangfan Yin, The Wistar InstituteFollow
Nancy R. Zhang, University of Pennsylvania,
Michael A. Davies, University of Texas MD Anderson Cancer CenterFollow
Meenhard Herlyn, The Wistar Institute
Katherine L. Nathanson, University of Pennsylvania,Follow

Document Type


Publication Date



This article has been peer reviewed. It is the author’s final published version in Cell Reports

Volume 21, Issue 7, November 2017, Pages 1936-1952

The published version is available at DOI: 10.1016/j.celrep.2017.10.052. Copyright © Garman et al.


Tumor-sequencing studies have revealed the widespread genetic diversity of melanoma. Sequencing of 108 genes previously implicated in melanomagenesis was performed on 462 patient-derived xenografts (PDXs), cell lines, and tumors to identify mutational and copy number aberrations. Samples came from 371 unique individuals: 263 were naive to treatment, and 108 were previously treated with targeted therapy (34), immunotherapy (54), or both (20). Models of all previously reported major melanoma subtypes (BRAF, NRAS, NF1, KIT, and WT/WT/WT) were identified. Multiple minor melanoma subtypes were also recapitulated, including melanomas with multiple activating mutations in the MAPK-signaling pathway and chromatin-remodeling gene mutations. These well-characterized melanoma PDXs and cell lines can be used not only as reagents for a large array of biological studies but also as pre-clinical models to facilitate drug development.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID